There’s no arguing against the ‘breast is best’ mantra at long-standing Melbourne based biotech Immuron, which bases its therapeutics on the goodness of colostrum (the antibody-rich milk produced by mammals after birth).
Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid
Immuron’s anti-NASH drug is IMM-124E, a colostrum-based compound. Colostrum is the first secretion (milk) from the mammary glands of cows post birth. Colostrum tends to be high in antibodies, although Immuron uses a very specific kind of colostrum achieve
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.
The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.